Literature DB >> 7739518

Developmental abnormalities in mice transgenic for bovine oncostatin M.

N Malik1, H S Haugen, B Modrell, M Shoyab, C H Clegg.   

Abstract

Oncostatin M belongs to the subfamily of hematopoietin cytokines that binds a receptor complex containing gp130. To date, only the human form of oncostatin M has been identified, and its evolutionary conservation is unresolved. We have isolated a bovine gene whose open reading frame encodes a precursor protein that is 58% identical to human oncostatin M. A comparison of the bovine and human amino acid sequences predicts significant similarity, including the four-alpha-helical-bundle structure and the placement of disulfide bridges. As with the human protein, bovine oncostatin M binds specific receptors on human H2981 cells and inhibits the proliferation of human A375 tumor cells and mouse M1 leukemia cells. To identify activities regulated in vivo, we injected bovine oncostatin M fusion genes containing various tissue-specific promoters into mouse embryos. The frequencies of transgenic mice were reduced significantly, suggesting that overexpression of the bovine cytokine is detrimental to normal mouse development. In addition to deaths associated with expression in neurons and keratinized epithelia, bovine oncostatin M caused abnormalities in bone growth and spermatogenesis, stimulated fibrosis surrounding islets in the pancreas, and disrupted normal lymphoid tissue development. This work establishes the existence of a nonprimate oncostatin M gene and provides the first demonstration that this cytokine can function in a pleiotropic manner in vivo. Information regarding bovine oncostatin M may help characterize the structure and function of this cytokine in other vertebrate species.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739518      PMCID: PMC230463          DOI: 10.1128/MCB.15.5.2349

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

Review 1.  Interleukin-6 in biology and medicine.

Authors:  S Akira; T Taga; T Kishimoto
Journal:  Adv Immunol       Date:  1993       Impact factor: 3.543

2.  Regulation of metallothionein--thymidine kinase fusion plasmids injected into mouse eggs.

Authors:  R L Brinster; H Y Chen; R Warren; A Sarthy; R D Palmiter
Journal:  Nature       Date:  1982-03-04       Impact factor: 49.962

3.  The genes for oncostatin M (OSM) and leukemia inhibitory factor (LIF) are tightly linked on human chromosome 22.

Authors:  T M Rose; M J Lagrou; I Fransson; B Werelius; O Delattre; G Thomas; P J de Jong; G J Todaro; J P Dumanski
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

4.  Leukemia inhibitory factor mediates an injury response but not a target-directed developmental transmitter switch in sympathetic neurons.

Authors:  M S Rao; Y Sun; J L Escary; J Perreau; S Tresser; P H Patterson; R E Zigmond; P Brulet; S C Landis
Journal:  Neuron       Date:  1993-12       Impact factor: 17.173

5.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

6.  Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors.

Authors:  E Sporeno; G Paonessa; A L Salvati; R Graziani; P Delmastro; G Ciliberto; C Toniatti
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

7.  Interleukin-6 signal transducer gp130 mediates oncostatin M signaling.

Authors:  J Liu; B Modrell; A Aruffo; J S Marken; T Taga; K Yasukawa; M Murakami; T Kishimoto; M Shoyab
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

8.  Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes.

Authors:  B Thoma; T A Bird; D J Friend; D P Gearing; S K Dower
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

9.  Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies.

Authors:  M M Shen; R C Skoda; R D Cardiff; J Campos-Torres; P Leder; D M Ornitz
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

10.  Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.

Authors:  X G Zhang; J J Gu; Z Y Lu; K Yasukawa; G D Yancopoulos; K Turner; M Shoyab; T Taga; T Kishimoto; R Bataille
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  22 in total

1.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 3.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

4.  Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption.

Authors:  R L Jilka; K Takahashi; M Munshi; D C Williams; P K Roberson; S C Manolagas
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 5.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

6.  Early differential expression of oncostatin M in obstructive nephropathy.

Authors:  Wafa M Elbjeirami; Luan D Truong; Ahmad Tawil; Wansheng Wang; Sara Dawson; Hui Y Lan; Ping Zhang; Gabriela E Garcia; C Wayne Smith
Journal:  J Interferon Cytokine Res       Date:  2010-07       Impact factor: 2.607

7.  Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand.

Authors:  Alfons S K de Hooge; Fons A J van de Loo; Miranda B Bennink; Diana S de Jong; Onno J Arntz; Erik Lubberts; Carl D Richards; Wim B vandDen Berg
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

8.  Naturally occurring dominant negative variants of Stat5.

Authors:  D Wang; D Stravopodis; S Teglund; J Kitazawa; J N Ihle
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

Review 9.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

Review 10.  Cytokines, leptin, and stress-induced thymic atrophy.

Authors:  Amanda L Gruver; Gregory D Sempowski
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.